ChemoID is a CLIA-certified and CAP-accredited drug response assay designed to help physicians select appropriate chemotherapy for an individual patient.
ChemoID is a functional test that uses a patient’s live tumor cells to indicate which chemotherapy agent (or combinations) will kill not only the bulk tumor cells but also the cancer stem cells (CSCs) that are the root of cancer and a known cause of cancer recurrence.
Targeting of CSCs alongside the bulk of other cancer cells is a new paradigm in cancer treatment. This constitutes an important advantage of the ChemoID approach over other diagnostic methods in the market.
During the assay, cancer stem cells and bulk tumor cells from an individual patient are exposed to chemotherapy drugs. The ChemoID assay measures the effect of actual doses of standard-of-care chemotherapies and reports them as a prioritized list of effective and ineffective chemotherapies.
The ChemoID drug response assay is designed to target CSCs to mitigate relapse.
ChemoID enables the most effective selection of chemotherapy drug(s), increasing patient survival and lowering treatment costs by eliminating unnecessary chemotherapies. The cost of cancer patient care can be significantly reduced with precisely defined chemotherapy.
ChemoID personalized chemotherapy assay predicts patient response to cancer chemotherapy, avoiding the severe side effects associated with administering ineffective chemotherapeutic drugs.
Entra in un mondo di opportunità su Hellspin dove ogni giro può trasformarsi in una vincita straordinaria.
